Kennedy Capital Management’s AstraZeneca AZN Stock Holding History

Kennedy Capital Management’s Portfolio AZN Stock Details AZN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$5.63M	Buy	29,684 +847	+3%	+$159K	0.1%	304
2026 Q1	$5.69M	Buy	28,837 +2,356	+9%	+$454K	0.12%	263
2025 Q4	$4.87M	Buy	26,481 +564	+2%	+$98.9K	0.1%	303
2025 Q3	$3.98M	Buy	25,917 +2,270	+10%	+$344K	0.09%	331
2025 Q2	$3.3M	Sell	23,647 -928	-4%	-$130K	0.08%	358
2025 Q1	$3.61M	Sell	24,575 -2,969	-11%	-$430K	0.09%	340
2024 Q4	$3.61M	Buy	27,544 +17,989	+188%	+$2.52M	0.08%	390
2024 Q3	$1.49M	Sell	9,555 -30,588	-76%	-$4.94M	0.03%	552
2024 Q2	$11.3M	Buy	40,143 +14,622	+57%	+$2.2M	0.24%	134
2024 Q1	$5.98M	Buy	+25,521	New	+$3.38M	0.12%	279

Other funds holding AZN

Evelyn Partners London $46.9B AUM

Investor AB Stockholm, Sweden $14.4B AUM 4.07% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Capital International Investors Los Angeles, California $484B AUM 34.9% 1-Year Est. Return

Norges Bank Oslo, Norway $1T AUM

Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return

Legal & General Group London, United Kingdom $480B AUM 42.84% 1-Year Est. Return

JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return

Kennedy Capital Management's AZN Position: Q2 2026 in Review

Kennedy Capital Management increased its AstraZeneca (AZN) stake by 2.9% in Q2 2026, buying an estimated $159K and bringing the position to 29,684 shares worth $5.63M. The position accounts for 0.1% of the portfolio, ranked #304.

Kennedy Capital Management first reported a position in AZN in Q1 2024 and has held it in 10 quarters since. The position peaked at $11.3M in Q2 2024. 1,495 funds tracked by Wall St. Rank hold AZN as of Q2 2026.

Kennedy Capital Management held 29,684 shares of AstraZeneca worth $5.63M as of Q2 2026.
Kennedy Capital Management bought 847 AstraZeneca shares in Q2 2026, an estimated $159K.
AstraZeneca made up 0.1% of Kennedy Capital Management's portfolio in Q2 2026, its #304 holding.
Kennedy Capital Management first reported a position in AstraZeneca in Q1 2024 and has held it in 10 quarters since.
Kennedy Capital Management's AstraZeneca position peaked at $11.3M in Q2 2024.
1,495 funds tracked by Wall St. Rank held AstraZeneca as of Q2 2026.

Based on Kennedy Capital Management's 13F filing for Q2 2026, filed 14 Aug 2026.